Discovery Labs Prices $23.5 Million Public Offering of Common Stock and Warrants
16 févr. 2011 09h10 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Feb. 16, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that it has priced an underwritten public offering of 10,000,000 units at a price to the...
Discovery Labs Announces Proposed Public Offering of Common Stock and Warrants
15 févr. 2011 16h02 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Feb. 15, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that it intends to offer, subject to market and other conditions, shares of its common...
Discovery Labs Provides Expanded Update Regarding Its Program for Surfaxin(R) U.S. Marketing Authorization
01 févr. 2011 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Feb. 1, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) is providing an expanded update regarding ongoing efforts to file a Complete Response intended to gain U.S....
Discovery Labs to Host a Conference Call to Provide an Overview of Its Program for Surfaxin(R) U.S. Marketing Authorization
27 janv. 2011 08h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Jan. 27, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) will host a conference call on Tuesday, February 1, 2011, at 10:00 AM EST. Management will provide an...
Discovery Labs Receives U.S. Patent Covering Pulmonary Surfactant and Protease Inhibitor Combination Products for Pulmonary Conditions
19 janv. 2011 07h30 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Jan. 19, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCOD) has been notified that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent...
Discovery Labs Announces that Nasdaq Hearing Panel Has Granted Request for Continued Listing on The NASDAQ Capital Market(R)
12 janv. 2011 07h30 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Jan. 12, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCOD) announced today that, on January 11, 2011, a NASDAQ Listing Qualifications Panel (the "Panel") determined...
Discovery Labs Provides Update Regarding Its Program for Surfaxin(R) U.S. Marketing Authorization
10 janv. 2011 07h30 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Jan. 10, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCOD), a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an...
Discovery Labs Announces Reverse Stock Split
27 déc. 2010 17h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Dec. 27, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of...
NIH Awards Discovery Labs Fast Track SBIR Grant to Support Development of Aerosolized KL4 Surfactant
16 déc. 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Dec. 16, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that the Company has been awarded Phase I of a Fast Track Small Business Innovation...
Discovery Labs Aerosurf(R) Improves Lung Function and Reduces Inflammation in a Dose-Dependent Fashion in Established Non-Clinical Model of Preterm Respiratory Distress Syndrome
07 déc. 2010 08h30 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Dec. 7, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), today announced that new Aerosurf® data in a study employing the well-established preterm lamb model...